Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo

Gene Therapy

Volumn 5, Issue 6, 1998, Pages 740-746

  Beer, S J ^a   Matthews, C B ^b   Stein, C S ^c   Ross, B D ^d   Hilfinger, J M ^b   Davidson, B L ^e  

^a Departments of Internal Medicine   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d TSRL INC   (United States)

^e University of Loica   (United States)

Author keywords

Adenovirus; Biodegradable microspheres; CNS; Gene therapy; PLGA; Polymers

Indexed keywords

NEUTRALIZING ANTIBODY; POLYGLACTIN; VIRUS ANTIBODY;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ENCAPSULATION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA;

EID: 0031824396     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300647     Document Type: Review

References (29)

1. Shapiro WR et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Nenrosiirg 1989; 71:1-9.
2. Mahaley MS Jr et al. National survey of patterns of care for brain-tumor patients. J Neiirosurg 1989; 71: 826-836.
3. Ross BD, Kim B, Davidson BL. Assessment of ganciclovir toxicity to experimental intracranial gliomas following recombinant adenoviral-mediated transfer of the herpes simplex virus thymidine kinase gene by magnetic resonance imaging and proton magnetic resonance spectroscopy. Clin Cancer Res 1995; 1: 651-657.
4. Chen SH et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc Natl Acad Sci USA 1994; 91: 3054-3057.
5. Perez-Cruet MJ et al. Adenovirus-mediated gene therapy of experimental gliomas. J Ncnrosci Res 1994; 39: 506-511.
6. Eck SL ct al. Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996; 7: 1465-1482.
7. Byrnes AP, Rusby JE, Wood MJA, Charlton HM. Adenovirus gene transfer causes inflammation in the brain. Neitrosciencc 1995; 66: 1015-1024.
8. Byrnes AP, MacLaren RE, Charlton HM. Immunological insta-bility of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression and demyelination. J Ncurosci 1996; 16: 3045-3055.
9. Yang Y, Greenough K, Wilson JM. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Therapy 1996; 3: 412-420.
10. Cowsar DR, Tice TR, Gilley RM, English JP. Poly (lactide-coglycolide) microcapsules for controlled release of steroids. In: KJ Widder, R Green (eds). Methods in Eiizymology, Vol 112. Academic Press: San Diego, 1985, pp 101-116.
11. Gref R et al. Biodegradable long-circulating polymeric nanospheres. Science 1994; 263: 1600-1603.
12. Pekarek KJ, Jacob JS, Mathiowitz E. Double-walled polymer microspheres for controlled drug release. Nature 1994; 367: 258-260.
13. Tice TR, Cowsar DR. Biodegradable controlled release parenteral systems. Pliannacol Technol 1984; 8: 26-31.
14. Barr D et al. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: comparisons between immunocompetent and immunodeficient inbred strains. Gene Therapy 1995; 2: 151-155.
15. Yang Y et al. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J Virol 1996; 70: 6370-6377.
16. Lemarchand P et al. Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA 1992; 89: 6482-6486.
17. Yalkowsky SH, Kuu W-Y. Multiple hole approach to zero-order release. J Pharm Sci 1985; 74: 926-933.
18. Ogawa Y, Okada H, Yamamoto M, Shimamolo T. In vivo release profiles of leuprolide acetate from microcapsules prepared with polylactic acids or copolydacticJglycolic) acids and in vivo degradation of these polymers. Chan Pharm Bull (Tokyo) 1988; 36: 2576-2581.
19. Cohen S et al. Controlled delivery systems for proteins based on poly(lacticJglycolic acid) microspheres. Pharm Res 1991; 8: 713-720.
20. Eldridge JH, Staas JK, Tice TR, Gilley RM. Biodegradable poly(DL-lactide-co-glycolide) microspheres. Res Iniinnnol 1992; 143: 557-563.
21. vanEssen D, Kikutanl H, Gray D. CD40 ligand-transduced costimulation of T cells in the development of helper function. Nature 1995; 378: 620-623.
22. Grewal IS, Xu J, Flavell RA. Impairment of antigen-specific T cell priming in mice lacking CD40 ligand. Nature 1995; 378: 617-620.
23. Eldridge JH et al. Biodegradable and biocompatible poly(DLlactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxinneutralizing antibodies. Infect Immun 1991; 59: 2978-2986.
24. Altman A, Dixon F. Immunomodifiers in vaccines. Adv Vet Sci Comp Med 1989; 33: 301-343.
25. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973; 52: 456-467.
26. Davidson BL et al. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3: 219-223.
27. Shewach DS et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1994; 1: 107-112.
28. Davidson BL et al. Expression of Escherichia coli ß-galactosidase and rat HPRT in the CNS of Macaca nnilatta following adenoviral mediated gene transfer. Exp Neural 1994; 125: 258-267.
29. Kim B, Chenevert TL, Ross BD. Growth kinetics and treatment response of the intracerebral rat 9L brain tumor model: a quantitative HI vivo study using magnetic resonance imaging. Clin Cancer Res 1995; 1: 643-650.